- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07832370
A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)
Phase 1/2 Open-Label Trial With Extended Follow-Up to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of ALN-6457 in Participants With Symptomatic Prion Disease
This study will test a Regeneron drug called ALN-6457 ("study drug") to see if it can help treat Prion Disease (PrD).
In PrD, the prion protein folds into an abnormal shape. These abnormal proteins build up in the brain and cause damage to brain cells, leading to problems with thinking, memory, and movement.
ALN-6457 is designed to reduce the amount of prion protein made in the brain. ALN-6457 works by targeting the genetic "instructions" that cells use to produce this protein, with the goal of slowing or stopping disease progression.
This study is looking at:
- What side effects ALN-6457 might cause
- How well ALN-6457 works
- What is the best dose of ALN-6457 for treating prion disease
- How much ALN-6457 is in the blood and Cerebrospinal Fluid (CSF, fluid that surrounds the brain and spinal cord) at different times
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Clinical Trials Administrator
- Phone Number: 844-734-6643
- Email: clinicaltrials@regeneron.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
-
Participant must meet all of the criteria under either:
- sporadic CJD as described in the protocol or
- genetic PrD, as described in the protocol
-
Has a Body Mass Index (BMI) <35 kg/m2 (inclusive) at the screening visit
-
Able to understand and complete trial-related questionnaires at screening
Key Exclusion Criteria:
- Clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease (excluding prion disease) that, as assessed by the investigator, may confound the results of the trial or pose an additional risk to the participant during trial participation
- Medical history of brain or spinal disease/injury that would interfere with the Lumbar Puncture (LP) procedure or CSF circulation, as described in the protocol
- Any contraindications to undergo a brain Magnetic Resonance Imaging (MRI)
- An established allergy or intolerance to local anesthetics
- Current history of bleeding diatheses that would increase risk of bleeding upon LP
- Any malignancy that is progressing or requires active treatment, as described in the protocol
- Attempted suicide, suicidal ideation with a plan that required hospital admission and/or change in level of care within 12 months prior to screening
NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Dose Escalation
|
Administered per the protocol
Other Names:
|
|
Experimental: Cohort Expansion
|
Administered per the protocol
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Time Frame: Through Week 156
|
Through Week 156
|
|
Severity of TEAEs
Time Frame: Through Week 156
|
Through Week 156
|
|
Percentage change in concentration of Neurofilament Light chain (NfL) in plasma from baseline
Time Frame: Through Week 130
|
Through Week 130
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Concentration of Prion Protein (PrP) in CSF
Time Frame: Through Week 130
|
Through Week 130
|
|
Change from baseline in concentration of PrP in CSF
Time Frame: Through Week 130
|
Through Week 130
|
|
Concentration of ALN-6457 and its major metabolites in plasma
Time Frame: Through Week 130
|
Through Week 130
|
|
Concentration of ALN-6457 and its major metabolites in CSF
Time Frame: Through Week 130
|
Through Week 130
|
|
Overall survival rate
Time Frame: At Week 52
|
At Week 52
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Protein Misfolding Disorder
- Neurodegenerative Disease
- Dementia
- Central Nervous System Disease
- Central Nervous System Infections
- PrD
- Symptomatic Prion Disease
- Sporadic Prion Disease
- Genetic Prion Disease
- Inherited Prion Disease
- Familial Prion Disease
- Gerstmann-Straussler-Scheinker syndrome (GSS)
- Fatal familial insomnia (FFI)
- Rapidly-Progressive Dementia
- Creutzfeldt-Jakob Disease (CJD)
- Fatal Familial Insomnia
- Prion-Associated Disorder
- Prion-Induced Disorder
- Neurological Decline
- Transmissible Spongiform Encephalopathy
Additional Relevant MeSH Terms
- Brain Diseases
- Nervous System Diseases
- Mental Disorders
- Genetic Diseases, Inborn
- Metabolic Diseases
- Infections
- Neurocognitive Disorders
- Sleep Wake Disorders
- Heredodegenerative Disorders, Nervous System
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Initiation and Maintenance Disorders
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Dementia
- Neurodegenerative Diseases
- Central Nervous System Diseases
- Proteostasis Deficiencies
- Creutzfeldt-Jakob Syndrome
- Central Nervous System Infections
- Insomnia, Fatal Familial
- Prion Diseases
- Gerstmann-Straussler-Scheinker Disease
Other Study ID Numbers
- ALN-6457-PD-25129
- 2026-526727-21-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD Sharing Time Frame
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD Sharing Access Criteria
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.